HYDERABAD, India, Dec 17, 2008—Satyam Computer Services announced that it is not going
ahead with its proposed acquisition of Maytas Properties and Maytas Infra, in light of the
feedback received from the Investor community.
Commenting on this decision, Satyam Chairman, Mr.Raju said, “We have been surprised by the
market reaction to this decision even though we were quite positive about the merits of the
acquisition. However, in deference to the views expressed by many investors, we have decided
to call off these acquisitions.”

10 December 2008, Mumbai:  Kotak Securities, the stock broking arm of the Kotak Mahindra group today announced the launch of Smart Order, a new service from, Kotak Securities that will help clients buy and sell stocks at the best possible rates from either of the stock exchanges – BSE or NSE.

Prasanth Prabhakaran, Senior Vice President & All India Head for Broking, commenting at the launch of this new service, said, “Smart Order is a novel concept introduced by Kotak Securities in the online broking space. Till date the online customer had to manually inspect and select the exchange to get a better price for his transaction. But with this system, Kotak Securities will help them get the best quoted price amongst NSE & BSE. There are price differences available in the market. Smart Order exploits these differences to benefit the customer. The investors can check the key features of this service on our website www.kotaksecurities.com.”

The Smart Order endeavors to offer the customer the best available price between NSE & BSE. Once he selects Smart Order to buy or sell, it executes the order at the best combination of price and quantity by doing a dynamic search. It is in fact better than having a dealer who decides the choice of stock exchange that will give you a better price and then executes the deal and all this instantly.

Smart Order is available without any extra charge and will be provided to all online clients of  Kotak Securities.

Hyderabad, India, December 10, 2008: Dr. Reddy’s Laboratories (NYSE:RDY) today announced that Betapharm AG, its wholly owned subsidiary, has received complete information on the preliminary result of the tender by the Allgemeine Ortskrankenkassen (AOK) for discount agreements for 47 of the 48 products pertaining to Betapharm, pursuant to § 130a SGB V.  betapharm has been tentatively offered 8 products in different regions of Germany covering the AOK-insured persons.
The tender procedure is yet to be concluded and is expected to face potential legal objections by several companies. On signing the final contracts with AOK, betapharm will be the sole supplier for AOK-insured persons for these 8 products in the awarded regions.
VS Vasudevan, President, European Operations, Dr. Reddy’s, said, “The preliminary results of the AOK tender establish betapharm’s competitiveness in the tender segment of the market in Germany. For the 8 products offered, we expect a significant increase in volume though at relatively lesser margins and for the balance portfolio, we expect the competitive intensity to continue.”
“Over the last few years, betapharm has aligned its sales force to strengthen relationships with doctors, pharmacies as well as channel partners. We leveraged Dr. Reddy’s vertical integration and global supply chain capabilities to strengthen the supply chain for this market. beta institute (the groups’ non-profit organization) complements these capabilities with the long-term goodwill it has built with the medical community through several years of Corporate Social Responsibility programmes. We believe that betapharm is well positioned to leverage all these strengths to continue to build a competitive business in all segments of the generics market in Germany”, said Satish Reddy, MD and COO, Dr. Reddy’s.

·       Plans Open Offer For Additional 20% Shares
·       Values Fem Care At Rs 282.4 Crores
Mumbai, November 21st, 2008: Dabur India Ltd today announced the acquisition of 72.15% of Fem Care Pharma Ltd (FCPL), a leading player in the women’s skin care products market, for Rs 203.7 Crores in an all-cash deal.

The board of directors of Dabur India Ltd approved the acquisition at a board meeting held in Mumbai today. The transaction ascribes a price per share of Rs 800, which translates into an equity valuation of Rs 282.4 Crores and an enterprise valuation of approximately Rs 300 Crores of Fem Care Pharma Ltd. Dabur will make an open offer for an additional 20% shares in the Company as required under the takeover regulations.

“Acquisition of Fem Care Pharma is in line with our strategy to aggressively expand Dabur’s scale of operations and strengthen its presence in the fast moving consumer goods (FMCG) space. This transaction would give Dabur an entry into the high-growth skin care market with an established brand name ‘FEM’. Further, Dabur also has the potential to extend the brand into newer and related skin care categories,” said Dr. Anand Burman, Chairman, Dabur India Ltd.

Fem Care Pharma Ltd, which has a leadership position in the fairness bleach category and a strong market position in hair removal and liquid soap category, is best known for its brand ‘FEM’. The other brands in its portfolio include Oxybleach cream, Botanica anti-ageing cream, Stratum colour protecting hair conditioners, SAKA men’s bleach and Bambi fabric softeners. FCPL, which reported a consolidated net profit of Rs 9.75 crores in the first half of the 2008-09 fiscal on a turnover of Rs 54.45 crores, also has a sizeable international market presence in markets such as Yemen, Maldives, Mauritius, Malaysia, UAE, Oman etc.

“The acquisition brings to Dabur a portfolio of well-known household brands that enjoy a pole position in their respective categories, offering us a strong platform to enter newer product categories and markets. Fem’s brands fit in well with Dabur’s future growth plans, both for India and international markets. As with our previous acquisition and subsequent integration of Balsara’s Hygiene and Home products businesses, the Fem Care Pharma Ltd transaction too would offer substantial synergies for expanding the reach of Fem’s brands in all our geographies as well as better management of overall system costs,” said Mr. Sunil Duggal, CEO, Dabur India Ltd.

“The strengths of Dabur will help expand the distribution of Fem’s brands across India and fuel faster growth for the company, both in India and abroad, thereby enhancing shareholder value,” said Ms Sunita Ramnathkar, Joint Managing Director, Fem Care Pharma Ltd.

“As Dabur gains access to Fem’s research capabilities, we believe it will be able to broaden the company’s product portfolio and further capitalize on the emerging opportunities in domestic and international markets,” said Mr. Sunil H. Pophale, Chairman & Managing Director, Fem Care Pharma Ltd.

KPMG Corporate Finance was the financial advisor to the promoters of Fem Care Pharma Ltd and Ambit Corporate Finance was the financial advisor to Dabur India Ltd.

Mumbai, November 19, 2008: Sejal Architectural Glass Ltd. (SAGL), a leading player in the architectural glass solutions, is in the process of setting up a world class 550 tonne per day capacity float glass plant at Jhagadia in the state of Gujarat. The estimated cost of the plant is Rs.500 crore spread across 150 acres of land and is expected to commence from April 2009.
Commenting on the development, Mr. Amrut Gada, Chairman and Managing Director, Sejal Architectural Glass Ltd. said, “This will be the first Indian float glass plant which is a 100 percent domestically promoted project. To part finance the project, we had tapped the capital market recently, and had an overwhelming response”.
Sejal has tied up with several big players for its supplies. The first phase of civil work under L&T is 71% completed whereas the second phase has already started. The company has tied up with Siemens and Kaypee for its electrical turnkey and Piping & mechanical turnkey respectively. The Greenfield float glass plant is expected to contribute 74-75% to the company’s total revenues after its commencement.